CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $32.86M, lower than 95% of all stocks globally
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
24.33MGBP32.86M · vs all stocks (USD)
Revenue (TTM)
0.00GBPvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
3.02xvs all stocks
52-Week Change
87.50%vs all stocks
Market Capitalization
24.33MGBP32.86M · vs all stocks (USD)
Enterprise Value
16.65MGBP22.48M · vs all stocks (USD)
Forward P/E
-0.0106xvs Biotechnology peers
Price to Book (MRQ)
35.80xvs Biotechnology peers
Enterprise to EBITDA
-6.66xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-110.91%vs Biotechnology peers
Return on Equity (TTM)
-2510.61%vs Biotechnology peers
Revenue (TTM)
0.00GBPvs all stocks (USD)
Gross Profit (TTM)
0.00GBPvs all stocks (USD)
EBITDA (TTM)
-2.50MGBP-3.37M · vs all stocks (USD)
Net Income (TTM)
-1.81MGBP-2.44M · vs all stocks (USD)
Operating Cash Flow (TTM)
-2.37MGBP-3.20M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.59MGBP-2.15M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00GBPFY2024 · Dec 31, 2024Operating Income
-2.68MGBP-3.61M · vs all stocks (USD)
Pre-tax Income
-2.78MGBPFY2024 · Dec 31, 2024Income Tax Expense
-295.87KGBPFY2024 · Dec 31, 2024Net Income
-2.48MGBPFY2024 · Dec 31, 2024EBIT
-2.78MGBPFY2024 · Dec 31, 2024EBITDA (Income Statement)
-2.75MGBPFY2024 · Dec 31, 2024Research & Development
1.16MGBPFY2024 · Dec 31, 2024Selling, General & Administrative
1.03MGBPFY2024 · Dec 31, 2024Other Operating Expenses
404.10KGBPFY2024 · Dec 31, 2024Non-operating Interest Income
6.24KGBPFY2024 · Dec 31, 2024Non-operating Interest Expense
1.98KGBPFY2024 · Dec 31, 2024EPS (Basic)
-0.0060GBPFY2024 · Dec 31, 2024EPS (Diluted)
-0.0060GBPFY2024 · Dec 31, 2024Basic Shares Outstanding
416.44MSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
416.44MSharesFY2024 · Dec 31, 2024Net Income from Continuing Operations
-2.48MGBPFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00GBPFY2024 · Dec 31, 2024Operating Cash Flow
-2.18MGBPFY2024 · Dec 31, 2024Free Cash Flow
-2.18MGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
236.90KGBPFY2024 · Dec 31, 2024Starting Profit (CF Statement)
-2.48MGBPFY2024 · Dec 31, 2024Stock-based Compensation
87.71KGBPFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
213.82KGBPFY2024 · Dec 31, 2024Capital Expenditures
-1.65KGBPFY2024 · Dec 31, 2024Purchase of Investments
-75.00KGBPFY2024 · Dec 31, 2024Sale of Investments
1.36MGBPFY2024 · Dec 31, 2024Net Investing Cash Flow
1.29MGBPFY2024 · Dec 31, 2024Other Financing Charges
502.00KGBPFY2024 · Dec 31, 2024Net Financing Cash Flow
502.00KGBPFY2024 · Dec 31, 2024Shares Outstanding
502.72MSharesUpdated Aug 4, 2026Float Shares
486.38MSharesUpdated Aug 4, 2026% Held by Insiders
4.97%vs all stocks
% Held by Institutions
19.38%vs all stocks
Total Cash (MRQ)
1.35MGBP1.83M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0030GBPUpdated Aug 4, 2026Total Debt (MRQ)
0.00GBPvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
1.52xvs Biotechnology peers
Book Value per Share (MRQ)
0.0010GBPUpdated Aug 4, 2026Total Assets
977.01KGBP1.32M · vs all stocks (USD)
Total Current Assets
884.87KGBPFY2024 · Dec 31, 2024Total Liabilities
1.52MGBPFY2024 · Dec 31, 2024Total Non-current Assets
92.14KGBPFY2024 · Dec 31, 2024Total Non-current Liabilities
0.00GBPFY2024 · Dec 31, 2024Total Current Liabilities
1.52MGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents
236.90KGBPFY2024 · Dec 31, 2024Accounts Payable
510.55KGBPFY2024 · Dec 31, 2024Common Stock (Book)
29.81MGBPFY2024 · Dec 31, 2024Retained Earnings
-65.91MGBPFY2024 · Dec 31, 2024Total Shareholders' Equity
-542.86KGBP-733.15K · vs all stocks (USD)
52-Week Low
1.39GBXUpdated Aug 4, 202652-Week High
19.40GBXUpdated Aug 4, 202652-Week Change
87.50%vs all stocks
Beta
3.02xvs all stocks
50-Day MA
4.18GBXUpdated Aug 4, 2026200-Day MA
5.97GBXUpdated Aug 4, 2026Avg 10-Day Volume
1.60MSharesUpdated Aug 4, 2026Avg 30-Day Volume
1.92MSharesUpdated Aug 4, 2026Diluted EPS (TTM)
0.00GBPUpdated Aug 4, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $32.86M, lower than 95% of all stocks globallySignificant
Market cap (USD): 32,861,830.824Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
SkinBioTherapeutics Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Inspiration Healthcare Group plc
Tier 1ProductionApproval-Gated PipelineRule
Aptamer Group Plc
Tier 1ProductionApproval-Gated PipelineRule
Rua Life Sciences Plc
Tier 1ProductionApproval-Gated PipelineRule
Context Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cindrigo Holdings Limited
Tier 1ProductionApproval-Gated PipelineFlowRisk
Kala Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Poolbeg Pharma plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Curiosis Inc.
Tier 1ProductionApproval-Gated PipelineRule
BioLineRx Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
American Battery Technology Company
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
ADC Therapeutics S.A.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Invivyd Inc.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown